Saturday, 31 October 2026European Markets

ALTRI SGPS, IMCD, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Basic Materials Sector.

Loading stream...

(vianews) - altri sgps (altr.ls) is among this list of stock assets with the highest dividend rate and return on equity on the basic materials sector.

financial asset price forward dividend yield return on equity
altri sgps (altr.ls) €5.28 5.26% 12.9%
imcd (imcd.as) €159.80 1.34% 17.19%
robertet (rbt.pa) €798.00 1.07% 13.85%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. altri sgps (altr.ls)

5.26% forward dividend yield and 12.9% return on equity

altri, sgps, s.a. produces and sells cellulosic fibers and energy in portugal and internationally. the company produces pulp products for various application including production of paper, tissue, and printing and writing papers; and dissolving pulp for use of textile production. it is also involved timber commercialization; forest management; production of forest-based renewable energy, such as industrial cogeneration from black liquor and biomass; real estate activities; and production of plants in nurseries, as well as the provision of services related with forests and landscapes. the company was incorporated in 2005 and is headquartered in porto, portugal.

earnings per share

as for profitability, altri sgps has a trailing twelve months eps of €0.21.

pe ratio

altri sgps has a trailing twelve months price to earnings ratio of 25.17. meaning, the purchaser of the share is investing €25.17 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.9%.

more news about altri sgps.

2. imcd (imcd.as)

1.34% forward dividend yield and 17.19% return on equity

imcd n.v. distributes, markets, and sells specialty chemicals and ingredients in the netherlands, rest of europe, the middle east, africa, north america, south america, and the asia-pacific. the company provides adhesives, core materials, filler reinforcements, flame retardants, masterbatch, modifiers, operating materials, pigments, plasticizers, processing aids, pur raw materials, rubber elastomers, solvents, stabilizers, thermoplastic elastomers, thermoplastics, thermoplastics, and other additives. it offers actives, uv sunscreens, rheology modifiers, thickeners, surfactants, emulsifiers, emollients, film formers, humectants, waxes, conditioners, hair styling polymers, solvent, solubilizers, pigments, pearls, powders and colorants, opacifiers, pearlizers, preservatives, antioxidants, fragrances, and essential oils. in addition, the company provides functional fillers, pigments, resins, and specialty solvents; taste, texture, nutrition, and function; and abrasives, acids, alkalines, anti-soil redeposition and foam control systems, bio-actives, biocides, bittering and bleaching agents, builders, capsules, chelating agents, concentrates/ready-to-use, corrosion and dye transfer inhibitors, disintegrants, dispersants, emulsifiers, enzymes, fluorinated polymers, oleo chemicals, optical brighteners, perfumes, dyes, phosphates, plasticisers, proteins, rheology modifiers and thickeners, silicones, solvents/diluents, taed, uv-filters, and waxes. further, it offers base oils; lubricants addictive; lubricants finished fluids; fuel additives; solvents, degreasers, and fuel compounds; and upstream, midstream, and downstream oil, gas, and energy. imcd n.v. was founded in 1995 and is headquartered in rotterdam, the netherlands.

earnings per share

as for profitability, imcd has a trailing twelve months eps of €5.12.

pe ratio

imcd has a trailing twelve months price to earnings ratio of 31.21. meaning, the purchaser of the share is investing €31.21 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.19%.

yearly top and bottom value

imcd's stock is valued at €159.80 at 07:30 est, under its 52-week high of €167.60 and way higher than its 52-week low of €109.05.

sales growth

imcd's sales growth is negative 4.1% for the current quarter and 0.1% for the next.

volume

today's last reported volume for imcd is 32999 which is 68.11% below its average volume of 103506.

revenue growth

year-on-year quarterly revenue growth declined by 5.6%, now sitting on 4.46b for the twelve trailing months.

more news about imcd.

3. robertet (rbt.pa)

1.07% forward dividend yield and 13.85% return on equity

robertet sa produces and sells perfumes, aromas, and natural products. the company operates in four segments: raw materials, fragrances, flavors, and active ingredients. it also produces organic essential oils and active ingredients. the company operates in north america, europe, the asia pacific, south america, caribbean, africa, and the middle east. robertet sa was founded in 1850 and is headquartered in grasse, france.

earnings per share

as for profitability, robertet has a trailing twelve months eps of €36.02.

pe ratio

robertet has a trailing twelve months price to earnings ratio of 22.15. meaning, the purchaser of the share is investing €22.15 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.85%.

moving average

robertet's value is below its 50-day moving average of €798.88 and below its 200-day moving average of €804.84.

more news about robertet.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com